Edition:
United States

Neptune Technologies & Bioressources Inc (NEPT.OQ)

NEPT.OQ on NASDAQ Stock Exchange Capital Market

3.05USD
17 Aug 2018
Change (% chg)

$-0.05 (-1.61%)
Prev Close
$3.10
Open
$3.13
Day's High
$3.15
Day's Low
$3.01
Volume
74,279
Avg. Vol
125,256
52-wk High
$4.46
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Neptune to issue 3rd series convertible bonds worth 6 bln won
Thursday, 1 Mar 2018 12:06am EST 

March 1 (Reuters) - Neptune Co <217270.KQ> ::* Says it will issue 3rd series unregistered and unsecured private convertible bonds, to raise 6 billion won in proceeds for operations .* Maturity date is April 2, 2021, coupon rate is 0 percent and yield to maturity is 0 percent for the bonds.* Conversion price is 15,364 won/share and conversion ratio is 100 percent .  Full Article

Neptune to issue 2nd series convertible bonds worth 24 bln won
Wednesday, 28 Feb 2018 11:50pm EST 

March 1 (Reuters) - Neptune Co <217270.KQ> ::* Says it will issue 2nd series unregistered and unsecured private convertible bonds, to raise 24 billion won in proceeds for operations and investment .* Maturity date is March 5, 2021, coupon rate is 0 percent and yield to maturity is 0 percent for the bonds.* Conversion price is 15,364 won/share and conversion ratio is 100 percent .  Full Article

Neptune Technologies & Bioressources Q3 ‍Net Income $1.3 Mln Vs $9.4 Mln
Wednesday, 14 Feb 2018 04:00pm EST 

Feb 14 (Reuters) - Neptune Technologies & Bioressources Inc ::NEPTUNE ANNOUNCES THIRD QUARTER RESULTS.NEPTUNE TECHNOLOGIES & BIORESSOURCES INC - ‍NET INCOME WAS $1.3 MILLION FOR CURRENT QUARTER, VERSUS $9.4 MILLION IN PRIOR YEAR​.NEPTUNE TECHNOLOGIES & BIORESSOURCES INC - ‍NON-IFRS OPERATING LOSS WAS $5.4 MILLION FOR CURRENT QUARTER, VERSUS $0.5 MILLION IN PRIOR YEAR​.  Full Article

Neptune And Tetra Bio-Pharma Sign Co-Development Agreement
Monday, 12 Feb 2018 08:00am EST 

Feb 12 (Reuters) - Tetra Bio Pharma Inc ::NEPTUNE AND TETRA BIO-PHARMA ENTER CO-DEVELOPMENT AGREEMENT FOR PURIFIED CANNABINOID OIL-BASED PRODUCTS TARGETING PAIN AND INFLAMMATION.TETRA BIO PHARMA- CO,NEPTUNE TECHNOLOGIES & BIORESSOURCES ENTERED DEAL FOR CO-DEVELOPMENT, COMMERCIALIZATION OF PURIFIED CANNABINOID OIL-BASED PRODUCTS.  Full Article

Neptune Technologies Extends Global Maxsimil Licence To Cannabis-Derived Products​
Monday, 27 Nov 2017 08:00am EST 

Nov 27 (Reuters) - Neptune Technologies & Bioressources Inc ::NEPTUNE TECHNOLOGIES & BIORESSOURCES - CO EXTENDS GLOBAL MAXSIMIL LICENCE TO CANNABIS-DERIVED PRODUCTS​.  Full Article

Neptune Q2 revenue C$6.8 million versus C$11.6 million
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - Neptune Technologies & Bioressources Inc :Neptune announces second quarter results.Q2 revenue C$6.8 million versus C$11.6 million.Neptune Technologies & Bioressources Inc - ‍gain of $23.9 million realized from sale of Krill Oil business​.Neptune Technologies & Bioressources Inc - ‍net income was $20.0 million for quarter, versus a net loss of $0.7 million in prior year​.  Full Article

Acasti Pharma reports Q1 loss per share c$0.19
Monday, 14 Aug 2017 05:30pm EDT 

Aug 14 (Reuters) - Acasti Pharma Inc -:Acasti Pharma reports first quarter fy 2018 financial results.Q1 loss per share c$0.19.  Full Article

Neptune reports about 45 pct fall in Q1 revenue
Monday, 14 Aug 2017 05:30pm EDT 

Aug 14 (Reuters) - Neptune Technologies & Bioressources Inc :Neptune announces first quarter results.Q1 revenue c$6.5 million versus c$11.8 million.Neptune Technologies & Bioressources Inc qtrly ‍net loss of $1.2 million versus net income of $1.3 million in prior year​.Neptune Technologies - "there exists a material uncertainty that casts substantial doubt about corporation's ability to continue as a going concern".  Full Article

Neptune appoints John Moretz as chairman
Tuesday, 8 Aug 2017 07:10am EDT 

Aug 8 (Reuters) - Neptune Technologies & Bioressources Inc ::Neptune announces resignation of Pierre Fitzgibbon as a director and the appointment of John Moretz as chairman.Neptune Technologies & Bioressources Inc - ‍John Moretz has been appointed chairman of board effective immediately to replace Fitzgibbon​.  Full Article

Acasti Pharma reports Q4 and FY 2017 financial results
Tuesday, 6 Jun 2017 04:30pm EDT 

June 6 (Reuters) - Acasti Pharma Inc ::Acasti Pharma reports fourth quarter and full-year 2017 financial results.Acasti Pharma Inc - ‍net loss for three-month period ended february 28, 2017 was $0.23 loss per share​.  Full Article